Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
B129693-50mg | 50mg | In stock | $227.90 | |
B129693-250mg | 250mg | In stock | $1,026.90 | |
B129693-1g | 1g | In stock | $3,693.90 |
IκBα kinase inhibitor. NF-κB inhibitor. Apoptosis inducer. Inhibits the release of proinflammatory cytokines. Inflammasome inhibitor. Platelet aggregation inhibitor.
Synonyms | 7-Chloro-1-cyclopropylmethyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one | CHEBI:92270 | Cyanovinyl)-p-tolylsulfone, beta-( | J-501956 | UNII-4Y5G2A4F6O | Curator_000002 | HMS3678M15 | (2E)-3-(4-methylbenzenesulfonyl)prop-2-enenitrile | NCGC00025272-03 | NCGC |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Biochemical and Physiological Mechanisms | BAY 11-7082, a potential anti-inflammatory agent, is an irreversible inhibitor of IKK α and phosphorylation of cytokine-inducible IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-α, NFKBIA; IC50=10 μM). In intact HUVECs, |
Storage Temp | Store at 2-8°C,Argon charged |
Shipped In | Wet ice |
Grade | Moligand™ |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Product Description | BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM. Also inhibiting components of the ubiquitin system. |
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (E)-3-(4-methylphenyl)sulfonylprop-2-enenitrile |
---|---|
INCHI | InChI=1S/C10H9NO2S/c1-9-3-5-10(6-4-9)14(12,13)8-2-7-11/h2-6,8H,1H3/b8-2+ |
InChi Key | DOEWDSDBFRHVAP-KRXBUXKQSA-N |
Canonical SMILES | CC1=CC=C(C=C1)S(=O)(=O)C=CC#N |
Isomeric SMILES | CC1=CC=C(C=C1)S(=O)(=O)/C=C/C#N |
WGK Germany | 3 |
PubChem CID | 5353431 |
Molecular Weight | 207.25 |
PubChem CID | 5353431 |
---|---|
ChEMBL Ligand | CHEMBL403183 |
CAS Registry No. | 19542-67-7 |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2302600 | Certificate of Analysis | Nov 20, 2024 | B129693 |
B2302650 | Certificate of Analysis | Nov 20, 2024 | B129693 |
B2302655 | Certificate of Analysis | Nov 20, 2024 | B129693 |
B2302646 | Certificate of Analysis | Nov 12, 2024 | B129693 |
B2302645 | Certificate of Analysis | Nov 12, 2024 | B129693 |
J2219134 | Certificate of Analysis | Aug 15, 2024 | B129693 |
J2127069 | Certificate of Analysis | Aug 01, 2023 | B129693 |
J2127070 | Certificate of Analysis | Aug 01, 2023 | B129693 |
I1511175 | Certificate of Analysis | Mar 14, 2023 | B129693 |
Solubility | Soluble in DMSO (>25 mg/ml), ethanol (15 mg/ml), methanol, dichloromethane, DMF (~25 mg/ml), and 1:3 DMF:PBS (pH 7.2) (~0.25 mg/ml). Insoluble in water, and sparingly soluble in aqueous buffers. |
---|---|
Sensitivity | Light & Air & Heat sensitive |
Melt Point(°C) | 134℃ |
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H315:Causes skin irritation H319:Causes serious eye irritation H302:Harmful if swallowed |
Precautionary Statements | P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of water. P321:Specific treatment (see ... on this label). P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P362+P364:Take off contaminated clothing and wash it before reuse. P330:Rinse mouth. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P301+P317:IF SWALLOWED: Get medical help. P337+P317:If eye irritation persists: Get medical help. P332+P317:If skin irritation occurs: Get medical help. |
WGK Germany | 3 |
1. Xue YL et al.. (2019) Silencing of STAT4 Protects Against Autoimmune Myocarditis by Regulating Th1/Th2 Immune Response via Inactivation of the NF-?B Pathway in Rats.. Inflammation, [PMID:30848408] |
2. Yu Zhong, Ouyang Ling. (2023) OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer. Discover Oncology, 14 (1): (1-14). [PMID:37642735] [10.1007/s12672-023-00778-0] |
1. Melisi D, Chiao PJ. (2007) NF-kappa B as a target for cancer therapy.. Expert Opin Ther Targets, 11 (2): (133-44). [PMID:17227230] [10.1021/op500134e] |
2. Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, Shpiro N, Cohen P. (2013) The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system.. Biochem J, 451 (3): (427-37). [PMID:23441730] [10.1021/op500134e] |
3. Chelko SP, Asimaki A, Lowenthal J, Bueno-Beti C, Bedja D, Scalco A, Amat-Alarcon N, Andersen P, Judge DP, Tung L et al.. (2019) Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy.. Circulation, 140 (18): (1491-1505). [PMID:31533459] [10.1021/op500134e] |
4. Wu L et al.. (2020) Angiotensin II induces RAW264.7 macrophage polarization to the M1-type through the connexin 43/NF-?B pathway.. Mol Med Rep, 21 (5): (2103-2112). [PMID:32186758] |
5. Kemp SB et al.. (2021) Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-?B-Mediated Production of CXCL1.. Cancer Res, 81 (16): (4305-4318). [PMID:34049975] |
6. Hu W et al.. (2019) Down-Regulation of Mir-107 Worsen Spatial Memory by Suppressing SYK Expression and Inactivating NF-?B Signaling Pathway.. Curr Alzheimer Res, 16 (2): (135-145). [PMID:30543171] |
7. Gao Y et al.. (2021) Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.. Signal Transduct Target Ther, 6 (398). [PMID:34795206] |
8. Hu Y et al.. (2019) Grape seed proanthocyanidin extract alleviates arsenic-induced lung damage through NF-?B signaling.. Exp Biol Med (Maywood), 244 (3): (213-226). [PMID:30869553] |
9. Ji JF et al.. (2018) ShenFu Preparation Protects AML12 Cells Against Palmitic Acid-Induced Injury Through Inhibition of Both JNK/Nox4 and JNK/NF?B Pathways.. Cell Physiol Biochem, 45 (4): (1617-1630). [PMID:29486473] |
10. Xue YL et al.. (2019) Silencing of STAT4 Protects Against Autoimmune Myocarditis by Regulating Th1/Th2 Immune Response via Inactivation of the NF-?B Pathway in Rats.. Inflammation, [PMID:30848408] |
11. Zhang X et al.. (2019) Soluble receptor for advanced glycation end-products enhanced the production of IFN-? through the NF-?B pathway in macrophages recruited by ischemia/reperfusion.. Int J Mol Med, 43 (6): (2507-2515). [PMID:30942429] |
12. Salomies L et al.. (2021) The developmental origins of heterodonty and acrodonty as revealed by reptile dentitions.. Sci Adv, 7 (51): (eabj7912). [PMID:34919438] |
13. Li X et al.. (2019) The Specific Inhibition of SOD1 Selectively Promotes Apoptosis of Cancer Cells via Regulation of the ROS Signaling Network.. Oxid Med Cell Longev, 2019 (9706792). [PMID:30911355] |
14. Sheng J et al.. (2021) Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.. Hepatology, 74 (4): (1971-1993). [PMID:33931882] |
15. Yu Zhong, Ouyang Ling. (2023) OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer. Discover Oncology, 14 (1): (1-14). [PMID:37642735] [10.1007/s12672-023-00778-0] |